NYSEAMERICAN:BPMX - Biopharmx Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.12
▲ +5.5565 (986.07%)

This chart shows the closing price for BPMX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biopharmx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BPMX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BPMX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Biopharmx in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.12.

This chart shows the closing price for BPMX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Biopharmx. This rating has held steady since January 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/29/2020Maxim GroupDowngradeBuy ➝ Hold
12/13/2019Maxim GroupReiterated RatingBuy$12.00
9/9/2019Maxim GroupSet Price TargetBuy$12.00
6/25/2019Maxim GroupSet Price TargetBuy$36.00
6/12/2019Maxim GroupSet Price TargetBuy$36.00
4/30/2019Maxim GroupLower Price TargetBuy$60.00
3/19/2019Maxim GroupReiterated RatingBuy$120.00
12/14/2018Roth CapitalReiterated RatingBuy
6/8/2018Maxim GroupReiterated RatingBuy$450.00
12/8/2017Maxim GroupReiterated RatingBuy$450.00
9/19/2017HC WainwrightReiterated RatingBuy$900.00
9/13/2017Maxim GroupLower Price TargetBuy$900.00 ➝ $450.00
9/13/2017Maxim GroupReiterated RatingBuy ➝ Buy$900.00 ➝ $450.00
9/13/2017HC WainwrightReiterated RatingBuy$900.00
6/15/2017HC WainwrightSet Price TargetBuy$900.00
6/3/2017Roth CapitalSet Price TargetBuy$900.00
6/2/2017Maxim GroupReiterated RatingBuy$900.00
5/5/2017Roth CapitalReiterated RatingBuy$900.00
5/5/2017Maxim GroupReiterated RatingBuy$900.00
5/5/2017HC WainwrightReiterated RatingBuy$900.00
5/4/2017Roth CapitalSet Price TargetBuy$900.00
5/4/2017HC WainwrightSet Price TargetBuy$900.00
5/4/2017Maxim GroupReiterated RatingBuy$900.00
3/28/2017HC WainwrightReiterated RatingBuy$900.00
3/27/2017HC WainwrightSet Price TargetBuy$900.00
3/25/2017Roth CapitalSet Price TargetBuy$900.00
2/9/2017Roth CapitalSet Price TargetBuy$900.00
1/6/2017Roth CapitalReiterated RatingBuy
1/6/2017Roth CapitalInitiated CoverageBuy$900.00
(Data available from 9/20/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Biopharmx logo
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $6.12
Low: $5.47
High: $6.30

50 Day Range

MA: N/A

52 Week Range

Now: $6.12
Low: $0.25
High: $6.30

Volume

336,508 shs

Average Volume

2,150,348 shs

Market Capitalization

$111.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Biopharmx?

The following Wall Street research analysts have issued stock ratings on Biopharmx in the last twelve months:
View the latest analyst ratings for BPMX.

What is the current price target for Biopharmx?

0 Wall Street analysts have set twelve-month price targets for Biopharmx in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Biopharmx in the next year.
View the latest price targets for BPMX.

What is the current consensus analyst rating for Biopharmx?

Biopharmx currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BPMX.

What other companies compete with Biopharmx?

How do I contact Biopharmx's investor relations team?

Biopharmx's physical mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company's listed phone number is +1-650-8895020. The official website for Biopharmx is www.biopharmx.com.